Literature DB >> 22846584

Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.

Imed Helal1, Berenice Reed, Robert W Schrier.   

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) is the most common single cause of end-stage renal disease after diabetes, hypertension and glomerulonephritis. The clinical course of ADPKD is highly variable. Even with optimal care and therapy monitoring, currently the progression of ADPKD is slowed but not stopped. Newer treatments will no doubt become available in the future, but their side effect profiles will always need to be considered. Therefore, markers to distinguish ADPKD patients with a poor versus a good prognosis will be helpful. Several risk factors influencing kidney disease progression in ADPKD have been identified in the current era. The present review will discuss the spectrum of early markers of ADPKD renal disease progression. Specifically, the volume of total kidney, hypertension, glomerular hyperfiltration, renal blood flow, microalbuminuria, uric acid, and urinary molecular markers will be discussed. On this background, implications for the prevention and treatment of kidney disease progression in ADPKD are also discussed.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846584     DOI: 10.1159/000341263

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  13 in total

1.  The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease.

Authors:  Bennur Esen; Emel Sağlam Gokmen; Mahmut Kaya; Burak Ozkan; Ahmet Engin Atay
Journal:  J Transl Int Med       Date:  2016-09-23

2.  A semi-automated "blanket" method for renal segmentation from non-contrast T1-weighted MR images.

Authors:  Henry Rusinek; Jeremy C Lim; Nicole Wake; Jas-mine Seah; Elissa Botterill; Shawna Farquharson; Artem Mikheev; Ruth P Lim
Journal:  MAGMA       Date:  2015-10-29       Impact factor: 2.310

Review 3.  ADPKD: clinical issues before and after renal transplantation.

Authors:  Piergiorgio Messa; Carlo Maria Alfieri; Emanuele Montanari; Mariano Ferraresso; Roberta Cerutti
Journal:  J Nephrol       Date:  2016-10-20       Impact factor: 3.902

4.  Biomarkers and surrogate endpoints in kidney disease.

Authors:  Erum A Hartung
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

Review 5.  Smelling the roses and seeing the light: gene therapy for ciliopathies.

Authors:  Jeremy C McIntyre; Corey L Williams; Jeffrey R Martens
Journal:  Trends Biotechnol       Date:  2013-04-17       Impact factor: 19.536

Review 6.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 7.  Consensus-Based Technical Recommendations for Clinical Translation of Renal Phase Contrast MRI.

Authors:  Anneloes de Boer; Giulia Villa; Octavia Bane; Michael Bock; Eleanor F Cox; Ilona A Dekkers; Per Eckerbom; Maria A Fernández-Seara; Susan T Francis; Bryan Haddock; Michael E Hall; Pauline Hall Barrientos; Ingo Hermann; Paul D Hockings; Hildo J Lamb; Christoffer Laustsen; Ruth P Lim; David M Morris; Steffen Ringgaard; Suraj D Serai; Kanishka Sharma; Steven Sourbron; Yasuo Takehara; Andrew L Wentland; Marcos Wolf; Frank G Zöllner; Fabio Nery; Anna Caroli
Journal:  J Magn Reson Imaging       Date:  2020-11-02       Impact factor: 5.119

8.  Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.

Authors:  Víctor Martínez; Jordi Comas; Emma Arcos; Joan Manel Díaz; Salomé Muray; Juan Cabezuelo; José Ballarín; Elisabet Ars; Roser Torra
Journal:  BMC Nephrol       Date:  2013-09-05       Impact factor: 2.388

Review 9.  Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.

Authors:  Laia Sans-Atxer; Dominique Joly
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-31

Review 10.  Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.

Authors:  Eric G Benz; Erum A Hartung
Journal:  Pediatr Nephrol       Date:  2021-01-21       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.